A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)

Autor: Watanabe, Satoshi, Furuya, Naoki, Nakamura, Atsushi, Shiihara, Jun, Nakachi, Ichiro, Tanaka, Hisashi, Nakao, Mika, Minato, Koichi, Seike, Masahiro, Sasaki, Shinichi, Kisohara, Akira, Takeuchi, Susumu, Honda, Ryoichi, Takamura, Kei, Kagamu, Hiroshi, Yoshimura, Kenichi, Kobayashi, Kunihiko, Kikuchi, Toshiaki
Zdroj: In European Journal of Cancer January 2024 197
Databáze: ScienceDirect
Externí odkaz: